To investigate the preventive effect of low-dose esketamine on catheter-related bladder discomfort(CRBD) in patients during anesthesia recovery period.
A total of 300 patients with benign prostatic hyperplasia admitted to our hospital from June 2021 to December 2024 were prospectively selected as the research subjects. The patients were divided into the control group and the observation group using simple sorting random method, with 150 patients in each group. The control group was intravenously injected with an equal volume of 0.9% sodium chloride solution after anesthesia induction, while the observation group was intravenously injected with a low dose of esketamine(0.25mg/kg). All included patients underwent transurethral prostatectomy treatment. The indicators related to CRBD and postoperative pain control were recorded. The secondary observation indicators included multiple dimensions such as perioperative rehabilitation and monitoring, drug safety, biological parameters, and long-term follow-up of urinary function.
The indicators related to CRBD, postoperative pain control and early rehabilitation, as well as the levels of neurotransmitters(such as substance P and acetylcholine) at 1 hour and 24 hours after extubation, and inflammatory factors(such as interleukin-6 and tumor necrosis factor-α) and the urinary function indicators(such as international prostate symptom score, residual urine volume, and maximum urine flow rate) at 1 month and 3 months after surgery in the observation group were all better than those in the control group(P<0.05), while there were no statistically significant differences in the operation time, bladder capacity at 24 hours after surgery, and the incidence of adverse drug reactions between the two groups(P>0.05).
Low-dose esketamine can effectively reduce the incidence and severity of CRBD in patients undergoing transurethral prostatectomy during the anesthesia recovery period, optimize postoperative pain control and early rehabilitation indicators, regulate neurotransmitter and inflammatory factor levels, and does not increase adverse drug reactions, and facilitate the recovery of bladder function after surgery.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |